Biochemotherapy vs chemotherapy alone
Biochemotherapy leads to higher toxicity (≥ G3) compared with chemotherapy (high certainty).
- RR 1.35 [1.14, 1.61]631 participantsHigh
Biochemotherapy leads to higher toxicity (≥ G3) compared with chemotherapy (high certainty).
Polychemotherapy probably leads to higher toxicity (≥ G3) compared with chemotherapy (moderate certainty).
It is very uncertain whether delayed chemotherapy changes toxicity – diarrhoea compared with immediate chemotherapy (very low certainty).
It is very uncertain whether delayed chemotherapy changes toxicity – stomatitis compared with immediate chemotherapy (very low certainty).
It is very uncertain whether delayed chemotherapy changes toxicity – nausea and vomiting compared with immediate chemotherapy (very low certainty).
Combination chemotherapy probably leads to higher toxicity ‐ early adverse events G3/4 compared with single‐agent chemotherapy (moderate certainty).
The review found no eligible studies for this question.
It is very uncertain whether ATRA in addition to chemotherapy changes cardiac toxicity grade III/IV compared with chemotherapy only (very low certainty).
It is very uncertain whether summary of findings table (subcomparison 2): second‐line… changes toxicity compared with control intervention alone (very low certainty).
Interferon + chemotherapy showed no clear difference in adverse event (neurotoxicity) compared with chemotherapy alone (low certainty).
Anti‐angiogenic drugs plus chemotherapy showed no clear difference in toxicity (≥ G3) compared with chemotherapy (low certainty).
Taxane‐containing chemotherapy showed no clear difference in cardiotoxicity (including grade 3/4 and congestive cardiac failure) compared with any chemotherapy without taxane (moderate certainty).
Anti‐EGFR antibody plus chemotherapy showed no clear difference in toxicity: grade 3 to 4 anaemia compared with chemotherapy alone (low certainty).
Anti‐EGFR antibody plus chemotherapy showed no clear difference in toxicity: grade 3 or 4 fatigue compared with chemotherapy alone (low certainty).
Anti‐CTLA4 monoclonal antibodies plus chemotherapy probably leads to higher toxicity (≥ G3) compared with chemotherapy (moderate certainty).
It is very uncertain whether anti‐EGFR antibody plus chemotherapy changes toxicity: grade 3 or 4 diarrhoea compared with chemotherapy alone (very low certainty).
Anti‐EGFR antibody plus chemotherapy showed no clear difference in toxicity: grade 3 or 4 hypokalaemia compared with chemotherapy alone (low certainty).
Anti‐EGFR antibody plus chemotherapy showed no clear difference in toxicity: grade 3 or 4 nausea ± vomiting compared with chemotherapy alone (low certainty).
It is very uncertain whether anti‐EGFR antibody plus chemotherapy changes toxicity: grade 3 or 4 diarrhoea ‐ seribantumab compared with chemotherapy alone (very low certainty).